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Abstract 
 
While the use of deep learning in drug discovery is gaining increasing attention, the lack of 
methods to computate reliable errors in prediction for Neural Networks prevents their application 
to guide decision making in domains where identifying unreliable predictions is essential, e.g. 
precision medicine. Here, we present a framework to compute reliable errors in prediction for 
Neural Networks using Test-Time Dropout and Conformal Prediction. Specifically, the algorithm 
consists of training a single Neural Network using dropout, and then applying it N times to both 
the validation and test sets, also employing dropout in this step. Therefore, for each instance in 
the validation and test sets an ensemble of predictions were generated. The residuals and 
absolute errors in prediction for the validation set were then used to compute prediction errors  
for test set instances using Conformal Prediction. We show using 24 bioactivity data sets from 
ChEMBL 23 that dropout Conformal Predictors are valid (i.e., the fraction of instances whose 
true value lies within the predicted interval strongly correlates with the confidence level) and 
efficient, as the predicted confidence intervals span a narrower set of values than those 
computed with Conformal Predictors generated using Random Forest (RF) models. Lastly, we 
show in retrospective virtual screening experiments that dropout and RF-based Conformal 
Predictors lead to comparable retrieval rates of active compounds. Overall, we propose a 
computationally efficient framework (as only N extra forward passes are required in addition to 
training a single network) to harness Test-Time Dropout and the Conformal Prediction 
framework, and to thereby generate reliable prediction errors for deep Neural Networks. 
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Introduction 
 
The application of deep learning in preclinical and clinical applications is gaining increasing 
attention1–4. While alternative algorithms used in computer-aided drug design are still widely 
used, such as Random Forest (RF) or Support Vector Machines, the versatility of deep learning 
in terms of the diversity of architectures or feature representations that can be used as input 
(e.g., from compound fingerprints to images of compounds5,6, cells7, or whole-slide pathology 
images8,9) renders it a suitable modelling strategy in diverse drug discovery applications10–13. 
However, the difficulty in interpreting how deep learning models work in most cases and the lack 
of methods to generate well-calibrated errors in prediction makes it challenging to apply Deep 
Neural Networks (DNN) to guide decision making in applications were knowing the reliability of 
individual predictions is essential e.g., personalized medicine14,15. 
 
The development of techniques for the estimation of the reliability of individual predictions is a 
major research area in machine learning, and it is of particular importance in the area of drug 
discovery, where both the predicted property and the associated uncertainty of this prediction 
needs to be considered for decision making16. A plethora of algorithmic approaches have been 
proposed to this end, including metrics based on the distance of test instances to those in the 
training set17,18, uncertainty estimation using Bayesian inference19–24, and methods based on the 
bagged variance across base learners in model ensembles25,26, among others27–29. In the 
context of deep learning, harnessing Test-Time Dropout predictions to model predictions 
uncertainty has gained increasing attention over the last years23,30. The main idea consists of 
training a Neural Network using dropout. Once trained, the network is applied on the test set to 
compute N forward passes using dropout as well. The variability across forward passes can be 
used to compute errors in prediction using Bayesian variational inference23,30. In addition to 
these Bayesian approaches23,30, we recently showed that Snapshot Ensembles and Conformal 
Prediction can be integrated to generate reliable confidence intervals for deep learning 
architectures31. However, the development of algorithms to model predictions uncertainty using 
deep learning and Conformal Prediction in the context of regression still remains vastly 
unexplored31.  
 
The application of Conformal Prediction in drug discovery is becoming widely used32–35 
because: (i) the predicted confidence intervals are easy to interpret (e.g., at a confidence level 
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of 90%, at least 90% of the predicted confidence regions will contain the true value)29; (ii) the 
sound mathematical framework on which Conformal Prediction is based36,37 guarantees that the 
confidence intervals are always valid (i.e., the fraction of instances for which the true value lies 
within the predicted region will not be smaller than the chosen confidence level) provided that 
the exchangeability principle is fulfilled, which is generally assumed when modelling preclinical 
data29,36,37, although this is not always the case38; (iii) each prediction consists of a confidence 
region in the case of regression, whose size depends on the user-defined Confidence Level 
(CL), and well-calibrated class probabilities in the case of classification37; (iv) Conformal 
Prediction can be used in combination with any machine learning algorithm and requires 
minimal computational cost beyond the training of the underlying algorithm29; (v) no 
parameterization is needed beyond the selection of a non-conformity function39. Hence, 
Conformal Prediction can be used in drug discovery to compute reliable errors in prediction at 
minimal computational cost.  
 
In the current work, we explore the possibility of utilizing Test-Time Dropout ensembles to 
generate Conformal Predictors, which we term Dropout Conformal Predictors, with the aim of 
computing errors for individual predictions guaranteed to be valid and easy to interpret. The 
approach – in line with the Test-Time Dropout validations described above – consists of 
applying a deep Neural Network trained using dropout regularization to the validation and test 
molecules repeatedly in order to generate an ensemble. The residuals and variance across the 
ensemble for the validation set are then used to generate a list of nonconformity values, that in 
turn serve to generate confidence intervals for the test set molecules. Using 24 IC50 data sets 
extracted from the ChEMBL database40, we show that this strategy permits to generate valid 
and efficient Conformal Predictors. We show that the average size of the computed confidence 
intervals are comparable to those calculated using RF-based Conformal Predictors. In addition, 
we interrogate the practical usefulness of Dropout Conformal Predictors to guide the selection of 
active molecules in retrospective virtual screening experiments. 
 
 
Methods 
 
Data Sets 
In this study we used 24 IC50 data sets extracted from ChEMBL version 2340, which have been 
previously modelled in several studies31,38. Briefly, we downloaded IC50 data for 24 diverse 
protein targets from ChEMBL using the chembl_webresource_client python module41–43. Only 
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IC50 values for molecules that satisfied the following filtering criteria were considered: (i) activity 
relationship equal to ‘=’, (ii) an activity unit equal to “nM”, (iii) target type equal to “SINGLE 
PROTEIN”, and (iv) organism equal to Homo sapiens. IC50 values were modeled in a 
logarithmic scale (pIC50 = −log10 IC50). The average pIC50 value was calculated when multiple 
pIC50 values were available for the same compound. Further information about the data sets is 
given in Table 1 and 31,38. The data sets are available in the Supporting Information of a 
previous study38. 
 
Table 1. IC50 data sets used in this study. 
ChEMBL target preferred 
name 
Target 
abbreviation 
Uniprot 
ID 
ChEMBL ID 
Number of 
bioactivity data 
points 
Tyrosine-protein kinase ABL ABL1 P00519 CHEMBL1862 773 
Acetylcholinesterase 
Acetylcholinester
ase 
P22303 CHEMBL220 3,159 
Serine/threonine-protein 
kinase Aurora-A 
Aurora-A O14965 CHEMBL4722 2,125 
Serine/threonine-protein 
kinase B-raf 
B-raf P15056 CHEMBL5145 1,730 
Cannabinoid CB1 receptor Cannabinoid P21554 CHEMBL218 1,116 
Carbonic anhydrase II Carbonic P00918 CHEMBL205 603 
Caspase-3 Caspase P42574 CHEMBL2334 1,606 
Thrombin Coagulation P00734 CHEMBL204 1,700 
Cyclooxygenase-1 COX-1 P23219 CHEMBL221 1,343 
Cyclooxygenase-2 COX-2 P35354 CHEMBL230 2,855 
Dihydrofolate reductase Dihydrofolate P00374 CHEMBL202 584 
Dopamine D2 receptor Dopamine P14416 CHEMBL217 479 
Norepinephrine transporter Ephrin P23975 CHEMBL222 1,740 
Epidermal growth factor 
receptor erbB1 
erbB1 P00533 CHEMBL203 4,868 
Estrogen receptor alpha Estrogen P03372 CHEMBL206 1,705 
Glucocorticoid receptor Glucocorticoid P04150 CHEMBL2034 1,447 
Glycogen synthase kinase-3 
beta 
Glycogen P49841 CHEMBL262 1,757 
HERG HERG Q12809 CHEMBL240 5,207 
Tyrosine-protein kinase 
JAK2 
JAK2 O60674 CHEMBL2971 2,655 
Tyrosine-protein kinase LCK LCK P06239 CHEMBL258 1,352 
Monoamine oxidase A Monoamine P21397 CHEMBL1951 1,379 
Mu opioid receptor Opioid P35372 CHEMBL233 840 
Vanilloid receptor Vanilloid Q8NER1 CHEMBL4794 1,923 
 
Molecular Representation 
All chemical structures were standardized to a common representation scheme using the 
python module standardizer (https://github.com/flatkinson/standardiser). Inorganic molecules 
were removed. The largest fragment was kept in order to filter out counterions, following 
standard procedures in the field44,45. Circular Morgan fingerprints46 were computed using RDkit 
(release version 2013.03.02)47. The radius was set to 2 and the fingerprint length to 2,048.  
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Machine Learning 
 
- Data Splitting  
The data sets were randomly split into a training set (70% of the data), a validation set (15%), 
and a test set (15%). For each data set, the training set was used to train a given network, 
whereas the validation set served to monitor the performance of the network during the training 
phase. In case of RF models, both the training and validation sets were used for model training. 
The predictive power of the final RF and DNN model was evaluated on the test set. The above 
split (and associated model training and testing) was repeated 20 times with random data set 
assignments.  
 
- Deep Neural Networks (DNN) 
DNNs were trained using the python library Pytorch48. We defined four hidden layers, composed 
of 1000, 1000, 100 and 10 nodes, respectively. The number of neurons in each layer was 
selected to be smaller than the input fingerprint size to reduce the chances of overfitting49. 
Rectified linear unit (ReLU) activation was used in all cases. The training data was processed in 
batches of size equal to 15% of the number of instances. We used Stochastic Gradient Descent 
with Nesterov momentum, which was set to 0.9 and kept constant during the training phase50. 
The networks were trained over 4,000 epochs, and early stopping was used in all cases, i.e., 
the training of a given network was stopped if the validation loss did not decrease after 300 
epochs. Cyclical learning rate annealing was implemented to train all networks51,52. Specifically, 
the learning rate was initially set to 0.005, and was decreased by 40% every 200 epochs. The 
learning rate was set back to the initial value (i.e., 0.005) after 1,000 epochs and the annealing 
process repeated in the same way as done for the first 1,000 epochs. Setting back the learning 
rate to a high value permits to escape local minima by sampling larger regions of the loss 
landscape51,52. We used either 10%, 20% or 50% dropout in the four hidden layers both during 
training and at test time2,53,54. The RMSE on the validation set was used as the loss function 
during the training of all networks. DNNs that failed to converge to RMSE values on the 
validation set smaller than 1.2 pIC50 units were discarded. 
 
- Random Forests (RF) 
RF models were trained using the python library scikit-learn55 as previously described31,38. 
Briefly, the default parameter values were used except for the number of trees, which was set to 
100, as using a larger number of trees does not result in increased generalization capability and 
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this value has been found to be a suitable choice in previous chemical structure-activity 
modelling studies56,57.  
 
Conformal Prediction 
 
- Dropout Conformal Prediction 
We describe below the steps followed to generate Conformal Predictors using Test-Time 
Dropout (Figure 1). We refer the reader to the work of Vovk et al.29,36,37 for further theoretical 
details about the Conformal Prediction framework.  
Firstly, a Neural Network was trained on the training and validation sets using dropout 
regularization53 (step 1). Subsequently, it was applied to the validation set using Test-Time 
Dropout to generate 100 predictions for each instance. In each forward pass, the dropout 
probability of each neuron in each layer was independent of other passes (step 2). The 
predicted value for each instance in the validation set,	𝑦#, was then calculated as the average 
across the 100 forward passes, and the standard deviation across passes, 𝜎, was used as a 
measurement of the prediction’s uncertainty58. Next (step 3), the residuals and the standard 
deviation across forward passes were used to generate a list of non-conformity values for the 
validation set as follows: 
Equation	1:						 ∝0=	
|𝑦0 − 𝑦45|
𝑒78
 
where 𝑦0 is the i
th instance in the validation set, and 𝑦45	and 𝜎0 	are the average and the standard 
deviation of the predicted activities for the ith instance across the 100 forward passes, 
respectively. The resulting list of non-conformity scores, 𝛼, was sorted in increasing order, and 
the percentile corresponding to the Confidence Level considered was selected, e.g., 𝛼:; for the 
80th percentile.  
 
The residuals were normalized using the natural exponential of the standard deviation across 
the 100 forward passes because comparative analysis of non-conformity metrics (as shown in 
Equation 1) revealed that the exponential scaling improves the efficiency of Conformal 
Predictors built on bioactivity data sets39. This scaling sets the upper value for the list of non-
conformity values to be equal to the largest residual in the validation set, as the exponential 
converts low 𝜎0 values to values close to unity.  
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Finally, the standard deviation across forward passes was used to calculate confidence regions 
for the data points in the test set as follows (step 4 in Figure 1): 
 
Equation	2:						𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒	𝑟𝑒𝑔𝑖𝑜𝑛 = 	𝑦F5 ± H𝑦I − 𝑦F5 H = 𝑦F5 ± (𝑒7K ∗ 	𝛼MN) 
 
Where 𝑦I is the j
th instance in the test set, 𝑦F5 	and 𝜎I are the average and the standard deviation 
of the predicted activities for the jth instance across 100 forward passes, respectively. 
Throughout this work we considered a Confidence Level of 80% unless otherwise stated, as this 
confidence level in our experience represents a generally suitable trade-off between efficiency 
and validity39. 
 
- Random Forests 
Cross-Conformal Predictors generated using Random Forests were used as a baseline for 
comparison. RF-based Cross-Conformal Predictors were generated as previously reported34,59. 
Briefly, RF models were trained on the training data using 10-fold cross validation. The cross-
validation residuals and the standard deviation across the Forest were used to calculate the list 
of non-conformity values for the training data39,57, which were in turn used to compute 
confidence intervals for the test set instances.   
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Results and Discussion 
We firstly compared the performance on the test set of DNN, using dropout probabilities in all 
layers of either 0.1, 0.25 or 0.5, and RF models (Figure 2). Overall, the performance of RF and 
DNN (as well as performance for different dropout probabilities) was comparable, with RMSE 
values on the test set in the 0.55-0.80 pIC50 units range, indicating that our choice of DNN 
architectures and model parameters were suitable to model these data sets. Moreover, the 
RMSE values on the test set are consistent with the expected errors in prediction for machine 
learning models trained on heterogeneous IC50 data sets extracted from ChEMBL60,61, and are 
in line with models reported in the literature for similar data sets38. Hence, the models obtained 
here are likely approaching the upper performance limit which can be obtained for the datasets 
used, which is also a likely factor behind the very similar performance obtained across methods. 
In the Conformal Prediction literature, two main metrics are used to assess the practical 
usefulness of Conformal Predictors, namely validity and efficiency29. A Conformal Predictor is 
considered to be valid (or well calibrated) if the confidence level matches the fraction of data 
points in the test set whose true value lies within the predicted confidence region. For instance, 
at a confidence level of 80%, the confidence intervals computed using a valid Conformal 
Predictor would contain the true value in at least 80% of the cases. The Conformal Predictors 
we generated using Test-Time Dropout are well calibrated (i.e., valid) for all dropout levels as 
well as for the RF-based models, as evidenced by the high correlation between the error rates 
and the confidence level (R2 > 0.99, P < 0.001; Supplementary Figure 1).  
Next, we evaluated the efficiency of the Conformal Predictors. The efficiency of a Conformal 
Predictor is determined by the size of the confidence regions. While a Conformal Predictor 
might be valid, it might not be useful in practice if the confidence regions span several pIC50 
units39,62. The average size of the confidence regions computed using RF-based and Dropout 
Conformal Predictors is comparable (Figure 3). However, the confidence intervals generated 
using Dropout Conformal Predictors span a smaller range of values. These results is line with 
previous results obtained for DNN-based Conformal Predictors generated using the Deep 
Confidence framework31, which is based on Snapshot Ensembles63. Taken together, these 
results indicate that the ensembles generated using Test-Time Dropout can be harnessed to 
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generate valid and efficient Conformal Predictors, with comparable validity and efficiency to RF-
based ones, and fewer models associated with very large confidence intervals. 
RF models are widely used in Conformal Predictors because the generation of an ensemble 
comes at no extra computational cost29,64. Moreover, the variance across base learners (i.e., 
bagged variance across the Trees in the Random Forest) conveys predictive signal to quantify 
the uncertainty of individual predictions, as the average RMSE on the test set increases with the 
variance among predictions25,26. As reported previously26, one should note that this numerical 
Pearson correlation between variance and prediction error is much weaker than the inflated 
correlation obtained by binning the test compounds on the basis of the predicted variance25,26,65. 
Most RF-based Conformal Predictors reported in the literature applied to regression tasks 
employ the standard deviation across base learners to scale the residuals and compute 
nonconformity scores39,66 (Equation 1). In practice, this means that the average RMSE on the 
test set is correlated with the size of the confidence interval computed using Conformal 
Predictors because, on average, the larger the variance across the ensemble, the larger the 
predicted confidence region will be (Equation 2). 
In the case of DNN, variational inference applied to Test-Time Dropout ensembles has been 
shown to generate well-calibrated confidence intervals, as their size strongly correlated with the 
average error in prediction24. In the current study we find that the bagged variance computed 
using Test-Time Dropout DNN ensembles spans a narrower range of values than the bagged 
variance calculated using RF (Figure 4 and Supplementary Figure 2), as evidenced by the 
larger spread of standard deviations between models (along the x-axis of Figure 4). A constant 
trend across data sets is that the higher the dropout probability, the higher the spread of 
standard deviations across models (Figure 4 and Supplementary Figure 2). Although Dropout 
Conformal Predictors generated using forward passes are valid, the smaller spread of variance 
values indicates that the size of the confidence intervals computed for test molecules with 
different absolute errors in prediction will be comparable. In other words, we observe a weaker 
correlation between the bagged variance and the absolute error in prediction for dropout DNN 
as compared to RF models. Hence, this indicates that the size of the predicted confidence 
intervals from dropout DNN models are less representative of the absolute error in prediction 
than those computed from RF models.  
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A major practical application of predicting uncertainty in a drug discovery setting is the 
prioritization of compounds for further experimental testing by selecting those with the lower 
bound of the predicted confidence region over a given bioactivity cut-off value29. For instance, if 
the goal was to find molecules with a potency better than 10nM (pIC50>7), we would consider for 
further testing those molecules with a predicted confidence region that spans at least that value. 
Therefore, we next sought to investigate the practical usefulness of RF-based and Dropout 
Conformal Predictors to guide prospective virtual screening campaigns. To this aim, we defined 
as true positives (i.e., the molecules we are interested in selecting) those molecules with the 
predicted lower bound of the confidence interval (i.e., the lower end of the interval) above a 
given cut-off value (note that in real-world virtual screens also factors such as scaffold diversity 
etc.. are of relevance67, which have not been considered in further detail in this analysis). Figure 
5 shows the distribution of (i) uncertain predictions: molecules for which the confidence region 
spans the cut-off value, (ii) false positives: molecules whose true pIC50 value is below the cut-off 
but the lower bound of the confidence region higher than the cut-off , (iii) true positives: 
molecules for which the lower bound of the confidence region and the true pIC50 value are both 
over the cut-off (these are the molecules we would primarily prioritize for further experimental 
testing), and (iv) false negatives: molecules for which the upper bound of the confidence region 
is below the cut-off value but the true pIC50 value is over the cut-off. We considered 5 integer-
valued pIC50 cut-off values in the analysis, ranging from 5 to 9.  
Overall, both the total number and fraction of true positives that are discovered are comparable 
across algorithms, suggesting that Dropout Conformal Predictors permit the discovery of 
compounds with an activity value over a certain pIC50 cut-off with comparable efficiency to RF 
ones, a trend that is observed across the pIC50 cut-off values considered. A similar trend is 
observed for the number of false positives, false negatives and molecules whose predicted 
confidence region spans the cut-off value of interest. Together, these results indicate that a 
comparable number of molecules with a potency over a cut-off value of interest would have 
been discovered by application of RF and Dropout Conformal Predictors.  
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Conclusions 
In this work we have shown that Test-Time Dropout represents an approach to generate 
ensembles from the training of a single Neural Network which can be used to generate valid and 
efficient Conformal Predictors at minimal computational cost (i.e., the cost of computing the 
extra forward passes). Comparable retrieval rates were obtained for RF-based and dropout 
Conformal Predictors in retrospective virtual screening experiments, where molecules with the 
predicted confidence intervals above a bioactivity cut-off value of interest were considered as 
active. Test-Time Dropout thus expands the set of algorithmic approaches available in 
preclinical drug discovery, which employs deep learning and is able to model the uncertainty of 
individual predictions. 
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Figures 
Figure 1  Workflow for the generation of Dropout Conformal Predictors, illustrated by the 
training of a single DNN. The first step (marked as 1 in the figure) consists of training a DNN 
using dropout. Subsequently, the network is applied to the validation set in 100 forward passes 
using random dropout (step 2). The residuals and variance across these 100 passes serve to 
compute a list of nonconformity scores (Equation 1). Next, the network is applied to the test set 
(step 3) 100 times using dropout as well. The resulting variance across forward passes is used 
to compute the point prediction and the confidence region (step 4 and Equation 2). 
Figure 2  Assessment of the predictive power on the test set. Mean RMSE values (+/- 
standard deviation) for the test set molecules averaged across 20 runs are shown. The  
modelling approaches considered (RF and DNN trained using increasingly larger dropout 
probabilities) showed high predictive power, with mean RMSE values in agreement with the 
uncertainty of heterogeneous data sets extracted from ChEMBL. The comparable performance 
of the models suggests that they are likely approaching the upper performance limit which can 
be obtained for the datasets used. 
Figure 3  Efficiency analysis of the generated models. Each box plot shows the distribution 
of the size of the confidence intervals generated for the test set molecules for a Confidence 
Level of 80% across 20 runs. Overall, the average interval size is comparable for Dropout and 
RF-based Conformal Predictors. However, the spread of the distributions for Dropout Conformal 
Predictors is smaller, indicating the absence of large confidence intervals.  
Figure 4  Relationship between the variance across forward passes and the absolute 
error in prediction. Each panel represents the correlation between the standard deviation 
across forward passes (x-axis; standard deviation across the forest in the case of RF) against 
the absolute error in prediction (y-axis) for the test set instances. Results for the four data sets 
with the highest number of datapoints are shown: Acetylcholinesterase (A), erbB1 (B), HERG 
(C), and JAK2 (D). Overall, the base learners (i.e., trees) in the case of RF models display a 
larger variation than DNN ensembles generated using Test-Time Dropout, as evidenced by the 
larger spread on the x-axis. Overall, the smaller spread of variance values in the case of DNN 
indicates that the size of the confidence intervals computed for molecules with different absolute 
errors in prediction will be more similar than those computed with RF-based Conformal 
Predictors.  
Figure 5  Comparison of retrieval rates for RF and Dropout Conformal Predictors. Each 
column corresponds to a bioactivity cut-off value (pIC50>5, 6, 7, 8, or 9). The bars represent the 
total number of test instances for which: (i) the confidence region spans the cut-off value (i.e., 
uncertain predictions; shown in turquoise), (ii) the lower bound of the confidence region is higher 
than the cut-off value but the observed pIC50 value is below the cut-off (i.e., false positives, 
shown in yellow), (iii) the lower bound of the confidence region is higher than the cut-off value 
and the observed pIC50 value is over the cut-off (i.e., true positives; shown in purple), and (iv) 
the upper bound of the confidence region is below the cut-off value but the observed pIC50 value 
is over the cut-off (i.e., false negatives; shown in red). The numbers on top of the bars indicate 
the percentage of true positives (i.e., molecules for which both the lower end of the confidence 
interval and the true pIC50 value are above the cut-off). The average values across the 20 runs 
are shown. Overall, both the total number and fraction of true positives that are discovered are 
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comparable across algorithms, suggesting that DNN Dropout Conformal Predictors permit the 
discovery of compounds with an activity value over a certain pIC50 cut-off with comparable 
efficiency to RF ones while avoiding models with excessive prediction uncertainty. 
Supplementary Figures 
Supplementary Figure 1  Calibration plots. Correlation between the estimated (1 - error rate) 
on the test set and the confidence level computed using (A) DNN dropout 0.1, (B) DNN dropout 
0.25, (C) DNN dropout 0.5, and (D) RF models train on the data sets with the largest number of 
datapoints. Comparable results were obtained for the other data sets. Overall, Dropout 
Conformal Predictors were found to be valid and well calibrated, as evidenced by the high 
correlation between the confidence level and the percentage of predictions whose true value 
lies within the predicted confidence region (1- error rate; y-axis).  
Supplementary Figure 2  Analysis of the variance of DNN-based predictions across 
forward passes. Distributions of the standard deviation across the ensemble for the test set 
instances are shown across the 20 runs. Overall, it can be seen that the variance across the 
ensemble is significantly larger for RF as compared to dropout-based DNN. This affects the 
spread of the distribution of intervals sizes, as shown in Figure 4. 
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